Preclinical data combining amivantamab (EGFR×c-MET BsAb) with pembrolizumab (anti–PD-1) in NSCLC showed increased infiltration of granzyme B–positive CD8+ T cells, expansion of central memory populations, and reduced tumor burden relative to either agent alone (245). Here, MET is linked to neoplasm.